Therapy Directory

Fludarabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Fludarabine as a study intervention. Browse Fludarabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1451

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Select Advanced Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Biliary Tract Carcinoma
Interventions: DISP-10; Biological
Lead sponsor: Dispatch Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2046
U.S. locations: 7
States / cities: Duarte, California • Newport Beach, California • Tampa, Florida + 4 more

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: Fludarabine, Cyclophosphamide, CAR-T; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Lymphoma, Myeloma, Leukemia
Interventions: Kappa CD28 T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2035
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Phase 1, Recurrent Melanoma, Refractory Melanoma
Interventions: Cyclophosphamide, Fludarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions: OBX-115; Biological
Lead sponsor: Obsidian Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Los Angeles, California • Stanford, California • Orlando, Florida + 5 more

Conditions: Relapsed/Refractory Myeloma
Interventions: Fludarabine phosphate, Cyclophosphamide, Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
Interventions: Cyclophosphamide, Fludarabine, Cetuximab, NK Cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Fludarabine, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions: CAR T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2040
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Large B-cell Lymphoma
Interventions: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™; Genetic · Drug · Device
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 63
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 51 more

Conditions: IgG4 Related Disease
Interventions: ACE1831, Lymphodepleting chemotherapy; Drug
Lead sponsor: Acepodia Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

About this Fludarabine clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Fludarabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fludarabine.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Fludarabine clinical trials

Filter and sort this therapy

Live official records

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

About this Fludarabine clinical trials directory page